Taking AD as an example, most advanced disease-modifying drugs under clinical development focus on β-amyloid or tau protein and therefore their treatment responses were usually demonstrated in animal models overexpressing these two targets, respectively. This evidence concerns the gene MAPT and Alzheimer disease.